Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

about

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.

P2860

Q48162932-B7236C94-F4C5-4799-8893-87AE029161F3

P2860

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

Item

http://www.wikidata.org/entity/Q48778777

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Imatinib dose reduction in pat ...... ained deep molecular response.

@en

Imatinib dose reduction in pat ...... ained deep molecular response.

@nl

type

Item

label

Imatinib dose reduction in pat ...... ained deep molecular response.

@en

Imatinib dose reduction in pat ...... ained deep molecular response.

@nl

prefLabel

Imatinib dose reduction in pat ...... ained deep molecular response.

@en

Imatinib dose reduction in pat ...... ained deep molecular response.

@nl

P1476

Imatinib dose reduction in pat ...... ained deep molecular response.

@en

P2093

Antonio Jiménez-Velasco

http://www.w3.org/2001/XMLSchema#string

Arturo Pereira

http://www.w3.org/2001/XMLSchema#string

CML Spanish Group (GELMC)

http://www.w3.org/2001/XMLSchema#string

Isabel Pérez

http://www.w3.org/2001/XMLSchema#string

Juan-Gonzalo Correa

http://www.w3.org/2001/XMLSchema#string

Juan-Luis Steegmann

http://www.w3.org/2001/XMLSchema#string

Santiago Osorio

http://www.w3.org/2001/XMLSchema#string

Sara Redondo

http://www.w3.org/2001/XMLSchema#string

Valentín García-Gutiérrez

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

P304

81-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-016-2839-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francisca Ferrer-Marín

Dolors Colomer

Fermin Sanchez-Guijo

Francisco Cervantes

P577

2016-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27717993

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

about

P2860

P2860

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921